News: R&D

Controllable self-replicating RNA vaccine delivered intradermally elicits cellular immunity - preprint manuscript posted

BALTIMORE, September 7, 2022 -- Elixirgen Therapeutics, Inc., a Baltimore-based, clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies using its controllable srRNA platform, announced today that it has posted a manuscript titled "Controllable self-replicating RNA vaccine delivered intradermally elicits cellular immunity" on the bioRxiv.org preprint server.

The link to the preprint manuscript: Controllable self-replicating RNA vaccine delivered intradermally elicits cellular immunity

About Elixirgen Therapeutics, Inc.

Elixirgen Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies using its controllable srRNA platform. The company has two products in Phase I/II clinical trials (ClinicalTrials.gov Identifiers: NCT04211714 and NCT04863131) using its proprietary c-srRNA platform. For more information visit ElixirgenTherapeutics.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in pharmaceutical research and development. Any forward-looking statements in this press release speak only as of the date of this press release, and Elixirgen Therapeutics undertakes no obligation to update or revise the statements in the future, even if new information becomes available.

Contact:

Media Relations
Elixirgen Therapeutics, Inc.
Phone: (443) 451-5300
Media@ElixirgenTherapeutics.com